Table 1.
Clinicopathological characteristics of patients.
| Pat ID | Age (years) | Sex | pT pN staging/side | MS status | RAS/BRAF mut* | Prev surgery/date | Metastatic sites | Prev CT | Disease status before COVID-19 | IgG anti-SARS-CoV-2 titre (U/ml) by ECLIA |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 68 | M | pT4a pN1b Right |
MSS | No | Only PT October 2019 |
Liver | Yes | SD | 1455.00 |
| 2 | 61 | M | pT3 pN0 Left |
MSS | Yes KRAS$ |
PT February 2019 Liver mets November 2019 |
Liver | Yes | PD | 188.40 |
| 3 | 63 | F | pT3 pN2a Left |
MSS | No | Only PT March 2019 |
Lung, peritoneum | Yes | SD | 1216.00 |
*
Both N- and K-RAS genes were assessed.
$
KRAS mutation (p.G12D) was revealed in the metastatic tissue by means of a tumour DNA sequencing restricted panel tests.
COVID-19, coronavirus disease 19; CT, chemotherapy; ECLIA, enhanced chemiluminescence immunoassay; mut, mutations; PT, primary tumour.